NY-AQARA
Aqara, a leading provider for smart home products, shares its latest plan of Matter support and integration for its existing and new devices. Aqara is fully committed to supporting Matter, and the Company has been working with the Connectivity Standards Alliance (CSA) and key stakeholders such as Apple, Google and Samsung on early testing programs to ensure a smooth transition towards the new standard. Aqara users will first gain access to Matter in December 2022 via the Aqara Hub M2 through an OTA (over-the-air) update, which will allow existing Aqara Zigbee devices to become compatible with Matter.
Other Aqara hubs, including the Hub M1S/M1S Gen 2, Hub E1, Camera Hub G3, and Camera Hub G2H Pro, will also receive similar OTA updates in the following months so that more Aqara users will be able to enjoy the benefits of Matter. The software updates are expected to first expose more than 40 Aqara Zigbee devices ranging from smart sensors and wireless switches to controller-type devices such as radiator thermostats and curtain controllers*. Through the Aqara hubs, these devices will be able to support Matter and connect with other third-party Matter devices. Some of these devices are listed below:
- Door & Window Sensor
- Temperature & Humidity Sensor
- Motion Sensor and Motion Sensor P1
- Vibration Sensor
- Smart Wall Switch (US)
- Smart Wall Switch H1 EU
- Smart Plug (US & EU)
- Single Switch Module T1
- Wireless Mini Switch
- Wireless Remote Switch H1
- Wireless Remote Switch (Single & Double Rocker)
- Radiator Thermostat E1
- Roller Shade Driver E1
- Curtain Driver E1
- Roller Shade Controller (Zigbee 1.2)
- LED Bulb and LED Bulb T1 (Tunable White)
Aqara aims to provide a comprehensive suite of Matter-compatible devices to global users, and its Matter device portfolio will continue to grow and incorporate other existing Zigbee devices in the coming future. Ultimately more than 160 Aqara Zigbee products belonging to over 10 different device categories are expected to receive Matter support.
Moreover, a new lineup of Thread-based devices will be introduced. Building upon the success of Aqara’s iconic door and window sensor as well as the motion sensor, the Company will refresh the designs of these two devices to adopt the Thread protocol - among other enhancements - to allow for native Matter support and direct connection with Matter controllers. The new sensors, i.e. the Door and Window Sensor P2 and the Motion and Light Sensor P2, are set to release in early 2023. As part of the ongoing partnership between NXP Semiconductors and Aqara, the Aqara Thread sensor will be showcased at the NXP demo table on the Matter launch event in Amsterdam.
An array of Thread-based Aqara devices is to follow including various smart sensors, dimmer switches, smart plugs, lights, and the next-gen smart home hub with multi-protocol support. The Aqara Hub M3 is designed to not only allow Aqara Zigbee devices to support Matter, but also serve as a Thread Border Router and a Matter Controller and Commissioner, which can directly connect and manage Thread and Matter-compatible smart home devices. The Company also plans to open its Aqara Home app to support third-party Matter devices.
Aqara strives to offer high-quality, smart home solutions that are accessible to everyone, specifically focusing on creating a seamless user experience. The Matter standard undoubtedly raises connected home experiences to the next level with unprecedented interoperability and simplicity, and Aqara will continue to enrich its Matter portfolio to offer users even more options for their smart homes and to expedite the mass adoption of smart homes worldwide.
* A full list of the first Aqara Zigbee devices to receive Matter support is available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005123/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release
SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom